Imatinib Mesylate | List of Frontiers open access articles

Original Research

Published on 13 May 2022

Imatinib Mesylate Reduces Voiding Frequency in Female Mice With Acute Cyclophosphamide-Induced Cystitis

Megan E. Perkins
Beatrice M. Girard
Susan E. Campbell
Margaret A. Vizzard

Frontiers in Systems Neuroscience

doi 10.3389/fnsys.2022.867875

6,120 views
3 citations

Case Report

Published on 06 Jan 2023

Case report: Giant cystic ileal gastrointestinal stromal tumor with an atypical intratumoral abscess

in Surgical Oncology

Linguang Chen
Jiannan Gu
Xuejun Zhang
Aijun Yu

Frontiers in Surgery

doi 10.3389/fsurg.2022.1056831

2,881 views
2 citations

Systematic Review

Published on 12 Nov 2024

Hotspots and future trends of dermatofibrosarcoma protuberans

in Skin Cancer

Zhen Meng
Rui Zhang
Zhihong Sun
Cong Fu
Zhiyu Li
Luying Wang
Ran Huo
Feng Xue

Frontiers in Oncology

doi 10.3389/fonc.2024.1399486

4,307 views
3 citations

Original Research

Published on 08 Oct 2024

Stretching the structural envelope of imatinib to reduce β-amyloid production by modulating both β- and γ-secretase cleavages of APP

in Medicinal and Pharmaceutical Chemistry

William J. Netzer
Anjana Sinha
Mondana Ghias
Emily Chang
Katherina Gindinova
Emily Mui
Ji-Seon Seo
Subhash C. Sinha

Frontiers in Chemistry

doi 10.3389/fchem.2024.1381205

2,037 views
1 citation

Review

Published on 25 Nov 2020

Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia

in Drug Metabolism and Transport

Yan Chen
Xiuhua Dong
QiuJu Wang
ZhiXi Liu
XinWei Dong
Sanjun Shi
HongTao Xiao

Frontiers in Pharmacology

doi 10.3389/fphar.2020.569843

9,287 views
19 citations

Original Research

Published on 22 Apr 2022

Imatinib Mesylate Reduces Neurotrophic Factors and pERK and pAKT Expression in Urinary Bladder of Female Mice With Cyclophosphamide-Induced Cystitis

Megan Perkins
Beatrice M. Girard
Susan E. Campbell
Grant W. Hennig
Margaret A. Vizzard

Frontiers in Systems Neuroscience

doi 10.3389/fnsys.2022.884260

6,903 views
3 citations

Original Research

Published on 08 Aug 2022

Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate

in Cancer Genetics

Ismail Siti Mariam
Ramli Norhidayah
Abu Bakar Zulaikha
Mohd Yunus Nazihah
Hassan Rosline
Ghazali Anis Kausar
Sulong Sarina
Husin Azlan
Ravindran Ankathil

Frontiers in Oncology

doi 10.3389/fonc.2022.720845

3,392 views
3 citations

Review

Published on 06 Sep 2022

Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors

in Gastrointestinal Cancers: Gastric and Esophageal Cancers

Xiangchen Hu
Zhe Wang
Peng Su
Qiqi Zhang
Youwei Kou

Frontiers in Oncology

doi 10.3389/fonc.2022.933248

5,346 views
9 citations

Case Report

Published on 30 May 2016

A Novel Four-Way Complex Variant Translocation Involving Chromosome 46,XY,t(4;9;19;22)(q25:q34;p13.3;q11.2) in a Chronic Myeloid Leukemia Patient

in Cancer Epidemiology and Prevention

Muhammad Asif
Mohammad Sarwar Jamal
Abdul Rehman Khan
Muhammad Imran Naseer
Abrar Hussain
Hani Choudhry
Arif Malik
Shahida Aziz Khan
Maged Mostafa Mahmoud
Ashraf Ali

Frontiers in Oncology

doi 10.3389/fonc.2016.00124

11,121 views
7 citations

Original Research

Published on 05 Aug 2022

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors

in Hematologic Malignancies

Manuela Mancini
Sara De Santis
Cecilia Monaldi
Fausto Castagnetti
Annalisa Lonetti
Samantha Bruno
Elisa Dan
Barbara Sinigaglia
Gianantonio Rosti
Michele Cavo

Frontiers in Oncology

doi 10.3389/fonc.2022.901132

3,939 views
7 citations

Case Report

Published on 01 Dec 2022

Case report: 10-year survival of a patient with a primary hepatic gastrointestinal stromal tumor

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Jie Lian
Meiyan Feng
Shumei Zhang
Haibo Lu

Frontiers in Oncology

doi 10.3389/fonc.2022.1035824

2,327 views
4 citations

Original Research

Published on 04 Feb 2020

Acute Treatment With Gleevec Does Not Promote Early Vascular Recovery Following Intracerebral Hemorrhage in Adult Male Rats

in Neurodegeneration

Mohammed Abbas
Elizabeth Haddad
Mary Hamer
Derek Nowrangi
John Zhang
William J. Pearce
Jiping Tang
Andre Obenaus

Frontiers in Neuroscience

doi 10.3389/fnins.2020.00046

4,325 views
1 citation

Case Report

Published on 05 Aug 2025

Gastrointestinal stromal tumor with secondary thrombocytosis: a case report of a high-risk patient

in Hematology

Na Li
Penghui Liu
Jiwu Guo
Jizhen Wang
Xinling Han
Jie Mao

Frontiers in Medicine

doi 10.3389/fmed.2025.1605819

1,856 views

Original Research

Published on 01 Feb 2021

Sunitinib and Imatinib Display Differential Cardiotoxicity in Adult Rat Cardiac Fibroblasts That Involves a Role for Calcium/Calmodulin Dependent Protein Kinase II

in Cardio-Oncology

Calum J. McMullen
Susan Chalmers
Rachel Wood
Margaret R. Cunningham
Susan Currie

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2020.630480

8,253 views
22 citations

Original Research

Published on 08 Jul 2025

ZFAS1/STAT3 axis modulates imatinib resistance of chronic myeloid leukemia cells through glucose metabolism reprogramming

in Hematologic Malignancies

Lan Yang
Yanqiu Han

Frontiers in Oncology

doi 10.3389/fonc.2025.1603060

2,053 views

Original Research

Published on 13 Aug 2019

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors

in Hematologic Malignancies

Maria Stella Pennisi
Stefania Stella
Silvia Rita Vitale
Adriana Puma
Sandra Di Gregorio
Chiara Romano
Elena Tirrò
Michele Massimino
Agostino Antolino
Sergio Siragusa

Frontiers in Oncology

doi 10.3389/fonc.2019.00764

6,031 views
15 citations

Articles

Imatinib Mesylate Reduces Voiding Frequency in Female Mice With Acute Cyclophosphamide-Induced Cystitis

Case report: Giant cystic ileal gastrointestinal stromal tumor with an atypical intratumoral abscess

Hotspots and future trends of dermatofibrosarcoma protuberans

Stretching the structural envelope of imatinib to reduce β-amyloid production by modulating both β- and γ-secretase cleavages of APP

Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia

Imatinib Mesylate Reduces Neurotrophic Factors and pERK and pAKT Expression in Urinary Bladder of Female Mice With Cyclophosphamide-Induced Cystitis

Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate

Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors

A Novel Four-Way Complex Variant Translocation Involving Chromosome 46,XY,t(4;9;19;22)(q25:q34;p13.3;q11.2) in a Chronic Myeloid Leukemia Patient

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors

Case report: 10-year survival of a patient with a primary hepatic gastrointestinal stromal tumor

Acute Treatment With Gleevec Does Not Promote Early Vascular Recovery Following Intracerebral Hemorrhage in Adult Male Rats

Gastrointestinal stromal tumor with secondary thrombocytosis: a case report of a high-risk patient

Sunitinib and Imatinib Display Differential Cardiotoxicity in Adult Rat Cardiac Fibroblasts That Involves a Role for Calcium/Calmodulin Dependent Protein Kinase II

ZFAS1/STAT3 axis modulates imatinib resistance of chronic myeloid leukemia cells through glucose metabolism reprogramming

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors